



USAID
FROM THE AMERICAN PEOPLE

USAID

Supply Chain Improvement Program (SCHIP) Activity

Overview

Goal:

- To attain sustainable access to and rational use of quality health products service delivery system.
- It will be a five year activity with expected funding level up to \$65,000,000.

Objectives

- Ensure the consistent availability of quality medical products at health service delivery points through an improved and matured supply chains & pharmaceutical services.
- Increase access to quality pharmaceutical services, improve rational use of quality pharmaceutical services medical products to achieve health outcomes
- Improve the efficiency and sustainability of the pharmaceutical systems

Geography

- At least 1200 health facilities (800 health centers and 400 Hospitals), EPSS warehouses, RHB and MOH

Result Framework

Goal: Attain sustainable access to and rational use of quality health products at all levels of the system

Objective 1: Maturity of the Supply Chain Functions and Operations Improved

- 1) Standardized measurement and tracking of supply chain maturity improved
- 2) The Supply Chain Workforce Capacity Strengthened
- 3) The technical oversight and coordination system of the pharmaceutical supply chain sector strengthened
- 4) Subnational level management and governance capacity improved

Objective 2: Access to and Rational Use of Medicines and Supplies at Health Facilities and Communities Improved

- 1) Health Center, Hospital and site-level pharmaceutical supply and services and practices improved
- 2) Access to community-based pharmacy services and community ownership enhanced

Objective 3: Supply Chain Systems and Pharmaceutical Services sustained and its efficiency improved

- 1) The engagement of the private sector in the pharmaceutical and supply chain services increased
- 2) Financial sustainability of the supply chain sector increased

New perspective

The new perspective expected from the planned SCHIP activity will be using and emphasizing on the following

- The activity will be a bilateral contract
- It emphasis pharmaceuticals systems maturity
- Private sector engagement
- Last mile medical product distribution
- Efficiency and sustainability
- Utilization of grant under contract
- In Country logistics and technical assistance